Forty years of combined oral contraception: the evolution of a revolution

---

• 1.
• Huxley A. Brave new world revisited. New York: Harper and Row, 1958: 138-139.
• 2.
• Huxley A. The population explosion. In: The human situation, a series of lectures delivered at the University of California, Santa Barbara, in 1969. London: Chatto and Windus, 1978: 40-55.
• 3.
• Haberlandt L. Hormonal sterilisation of female animals. Munchner Med Wochenschr 1921; 68: 1577-1588.
• 4.
• Sturgis SH, Albright R. Mechanism of estrin therapy in the relief of dysmenorrhoea. Endocrinol 1940; 26: 68-73.
• 5.
• Diczfalusy E. Gregory Pincus and steroidal contraception: a new departure in the history of mankind. J Steroid Biochem 1979; 11: 3-11.
• 6.
• Archer DF, Maheux R, Del Conte A, O'Brien FB. A new low-dose monophasic combination oral contraceptive with levonorgestrel 100 µg and ethinyl oestradiol 20 µg. Contraception 1997; 55: 139-144.
• 7.
• Ketting G. The relative reliability of oral contraceptives: findings of an epidemiological study. Contraception 1988; 37: 343-353.
• 8.
• National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, AusInfo, 1999.
• 9.
• Jones ES, Forest JD. Contraceptive failure in the United States: revised estimates from the 1982 National Survey of Family Growth. Fam Plann Perspect 1989; 21: 103-109.
• 10.
• Fraser IS. Benefits and risks of steroidal contraception. In: Salamonsen LA, editor. Hormones and women's health: the reproductive years. Amsterdam: Harwood Academic Publishers, 2000: 161-171.
• 11.
• Schlesselman JJ, Collins JA. The influence of steroids on gynecologic cancers. In: Fraser IS, Jansen RPS, Lobo RA, Whitehead MI, editors. Estrogens and progestogens in clinical practice. London: Churchill Livingstone, 1998: 831-864.
• 12.
• Mishell DR Jr. Non-contraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982; 142: 809-818.
• 13.
• Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986; 293: 359-362.
• 14.
• Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306: 182-184.
• 15.
• Chiaffarino F, Parazzini F, LaVecchia C, et al. Oral contraceptive use and benign gynecologic conditions. Contraception 1998; 57: 11-18.
• 16.
• Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144: 640-649.
• 17.
• Bagwell MA, Coker AL, Thompson SJ, et al. Primary infertility and oral contraceptive steroid use. Fertil Steril 1995; 63: 1161-1166.
• 18.
• Goldzieher JW, Moses LE, Averkin E, et al. A placebo-controlled, double-blind crossover investigation of the side-effects attributed to oral contraception. Fertil Steril 1971; 22: 609-618.
• 19.
• Graham CA, Ramos R, Bancroft J, et al. The effects of steroidal contraceptives on the well-being and sexuality of women. Contraception 1995; 52: 363-370.
• 20.
• Farmer RDT, Lawrenson RA, Todd JC, et al. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Data Base and the UK MediPlus Data Base. Hum Reprod Update 1999; 5: 688-706.
• 21.
• Edwards RG, Cohen J, editors. Reproductive choices in 2000: the relative safety of current oral contraceptives. Hum Reprod Update 1999; 5: 563-771.
• 22.
• Croft P, Hannaford P. Risk factors for acute myocardial infarction in women. BMJ 1995; 298: 165-168.
• 23.
• Thorogood M. Stroke and steroidal hormonal contraception. Contraception 1998; 57: 157-167.
• 24.
• Carr BA, Ory HW. Estrogen and progestin components of oral contraception: relationship to vascular disease. Contraception 1997; 55: 267-272.
• 25.
• Collaborative Group on Hormonal Risk Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
• 26.
• Rooks JB, Ory HW. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. JAMA 1979; 242: 644-648.
• 27.
• Irwin KL, Rosero-Bixby L, Oberle MW, et al. Oral contraceptives and cervical cancer risk in Costa Rica: detection bias or causal association? JAMA 1988; 259: 59-66.
• 28.
• World Health Organization, Family and Reproductive Health. Improving access to quality care in family planning: medical eligibility criteria for initiating and continuing use of contraceptive methods. Geneva: World Health Organization, 1995.
• 29.
• Hannaford P, Webb A. Evidence-guided prescribing of combined oral contraceptives: a consensus statement. Contraception 1996; 54: 125-129.